We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-11.77%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.71B
AUM Growth
+$160M
(+10%)
Cap. Flow
+$357M
Cap. Flow
% of AUM
20.9%
Top 10 Holdings %
Top 10 Hldgs %
44.59%
Holding
58
New
13
Increased
12
Reduced
1
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bausch Health
BHC
|
+$148M |
| 2 |
STJ
St Jude Medical
STJ
|
+$68.1M |
| 3 |
AbbVie
ABBV
|
+$50.2M |
| 4 |
Alkermes
ALKS
|
+$47.4M |
| 5 |
Biogen
BIIB
|
+$46.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$67.9M |
| 2 |
HCA Healthcare
HCA
|
+$67.6M |
| 3 |
MJN
Mead Johnson Nutrition Company
MJN
|
+$39.5M |
| 4 |
SUNE
SUNation Energy
SUNE
|
+$38.9M |
| 5 |
Labcorp
LH
|
+$37.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.57% |
| 2 | Consumer Staples | 0% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Teva Pharmaceuticals
TEVA
$41.2B
| $120M | 7.05% |
2,250,000
+450,000
| +25% | +$26.4M |
|
2
Viatris
VTRS
$20.7B
| $85.7M | 5.02% |
1,850,000
+600,000
| +48% | +$29M |
|
|
MDCO
3
DELISTED
Medicines Co
MDCO
| $79.4M | 4.65% |
2,500,000
+300,000
| +14% | +$9.8M |
|
4
Brookdale Senior Living
BKD
$3.49B
| $79.4M | 4.65% |
5,000,000
+2,750,000
| +122% | +$42M |
|
|
NUVA
5
DELISTED
NuVasive, Inc.
NUVA
| $73M | 4.27% |
1,500,000
+400,000
| +36% | +$18.2M |
|
|
STJ
6
DELISTED
St Jude Medical
STJ
| $68.8M | 4.03% |
+1,250,000
| New | +$68.1M |
|
|
SEM
7
DELISTED
Select Medical
SEM
| $65.8M | 3.86% |
10,347,200
+1,995,200
| +24% | +$10.7M |
|
8
LivaNova
LIVN
$4.45B
| $64.8M | 3.79% |
1,200,000
| – | – |
|
9
Orthofix Medical
OFIX
$477M
| $62.3M | 3.65% |
1,500,000
| – | – |
|
10
Nektar Therapeutics
NKTR
$2.41B
| $61.9M | 3.62% |
300,000
+66,667
| +29% | +$12.8M |
|
|
GHDX
11
DELISTED
Genomic Health, Inc.
GHDX
| $60.9M | 3.57% |
2,458,100
| – | – |
|
|
LDRH
12
DELISTED
LDR HOLDINGS CORP COM STK
LDRH
| $57.4M | 3.36% |
2,250,000
+1,716,600
| +322% | +$35.9M |
|
|
13
CALL
Teva Pharmaceuticals
TEVA
$41.2B
| $53.5M | 3.13% |
+1,000,000
| New | +$58.7M |
|
|
14
Bausch Health
BHC
$2.25B
| $52.6M | 3.08% |
+2,000,000
| New | +$148M |
|
|
15
AbbVie
ABBV
$455B
| $51.4M | 3.01% |
+900,000
| New | +$50.2M |
|
16
CALL
Gilead Sciences
GILD
$163B
| $45.9M | 2.69% |
+500,000
| New | +$45.1M |
|
|
17
Biogen
BIIB
$30.7B
| $45.6M | 2.67% |
+175,000
| New | +$46.2M |
|
18
Tenet Healthcare
THC
$21.8B
| $43.4M | 2.54% |
1,500,000
| – | – |
|
19
Quest Diagnostics
DGX
$25.9B
| $42.9M | 2.51% |
600,000
| – | – |
|
|
UAM
20
DELISTED
Universal American Corp
UAM
| $41.9M | 2.46% |
5,875,000
| – | – |
|
|
MASI
21
DELISTED
Masimo
MASI
| $41.8M | 2.45% |
1,000,000
| – | – |
|
|
22
Alkermes
ALKS
$8.39B
| $41M | 2.4% |
+1,200,000
| New | +$47.4M |
|
|
MDVN
23
DELISTED
MEDIVATION, INC.
MDVN
| $37.9M | 2.22% |
+825,000
| New | +$29.9M |
|
|
ARIA
24
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $34.5M | 2.02% |
5,405,235
| – | – |
|
|
ELGX
25
DELISTED
Endologix Inc
ELGX
| $32.3M | 1.89% |
+386,450
| New | +$31.9M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q1 2016 Portfolio in Review
As of Q1 2016, Camber Capital Management held 58 positions worth $1.71B, up 10% from $1.55B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Camber Capital Management deployed $357M of net new capital in Q1 2016, opening 13 new positions and adding to 12 existing holdings. Its largest new stake was Bausch Health: 2,000,000 shares worth $52.6M.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 65% a quarter earlier, followed by Consumer Staples and Technology.
On the sell side, the largest reduction was CARDICA INC COM NEW (DE), an estimated $6 trimmed.
- Camber Capital Management's largest Q1 2016 buy was Bausch Health: 2,000,000 shares worth $52.6M.
- Camber Capital Management added most to Brookdale Senior Living in Q1 2016, an estimated $42M increase.
- Camber Capital Management's biggest Q1 2016 reduction was CARDICA INC COM NEW (DE), cutting an estimated $6.
- Camber Capital Management fully exited AstraZeneca in Q1 2016, selling an estimated $67.9M.
- Camber Capital Management's ten largest holdings make up 45% of its $1.71B portfolio in Q1 2016.
- Camber Capital Management opened 13 new positions and closed 10 in Q1 2016.
- Camber Capital Management's portfolio value rose 10% quarter-over-quarter to $1.71B.
Based on Camber Capital Management's 13F filing for Q1 2016, filed 13 May 2016.